Amal Ephrem
Overview
Explore the profile of Amal Ephrem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ephrem A, Epstein A, Stephens G, Thornton A, Glass D, Shevach E
Eur J Immunol
. 2013 Jun;
43(9):2421-9.
PMID: 23722868
Treg cells express high levels of the glucocorticoid-induced tumor necrosis factor-related receptor (GITR), while resting conventional T (Tconv) cells express low levels that are increased upon activation. Manipulation of GITR/GITR-Ligand...
2.
Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al.
Blood
. 2007 Oct;
111(2):715-22.
PMID: 17932250
The clinical use of intravenous immunoglobulin (IVIg) based on its immunomodulatory and anti-inflammatory potential remains an ongoing challenge. Fcgamma receptor-mediated effects of IVIg, although well elucidated in certain pathologies, cannot...
3.
Siberil S, Elluru S, Negi V, Ephrem A, Misra N, Delignat S, et al.
Transfus Apher Sci
. 2007 Sep;
37(1):103-7.
PMID: 17765663
Initially used for the treatment of immunodeficiencies, intravenous immunoglobulin (IVIg) has increasingly been used as an immunomodulatory agent in immune thrombocytopenic purpura, autoimmune neuropathies, systemic lupus erythematosus, myasthenia gravis, Guillain-Barré...
4.
Elluru S, Duong van Huyen J, Prost F, Delignat S, Bayry J, Ephrem A, et al.
Immunol Lett
. 2006 Sep;
107(1):58-62.
PMID: 16952403
Intravenous immunoglobulin (IVIG) is increasingly used in the treatment of diverse immune-mediated disorders. Since several preparations of IVIG are available for therapy, it is possible that different manufacturing processes might...
5.
Bayry J, Bayary J, Dasgupta S, Misra N, Ephrem A, Duong van Huyen J, et al.
Int Immunopharmacol
. 2006 Mar;
6(4):528-34.
PMID: 16504915
Intravenous immunoglobulin (IGIV) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases in addition to supportive therapy of immunodeficient patients. IGIV is beneficial in several diseases,...
6.
Misra N, Bayry J, Bayary J, Dasgupta S, Ephrem A, Duong van Huyen J, et al.
Clin Rev Allergy Immunol
. 2006 Jan;
29(3):201-5.
PMID: 16391394
Intravenous immunoglobulin (IVIg) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases, and in supportive therapy of immunodeficient patients. Available clinical and experimental evidence suggests, however,...
7.
Misra N, Bayry J, Ephrem A, Dasgupta S, Delignat S, Duong van Huyen J, et al.
J Neurol
. 2005 Jun;
252 Suppl 1:I1-6.
PMID: 15959666
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg...